One form ofC3-convertase, also known as C4b2b (formally known as C4b2a), is formed by a heterodimer of activated forms of C4 and C2.[10] It catalyzes theproteolytic cleavage of C3 intoC3a andC3b, generated during activation through the classical pathway as well as thelectin pathway. C3a is ananaphylotoxin and the precursor of some cytokines such asASP, and C3b serves as anopsonizing agent.Factor I can cleave C3b into C3c and C3d, the latter of which plays a role in enhancingB cell responses. In the alternative complement pathway, C3 is cleaved by C3bBb, another form of C3-convertase composed of activated forms of C3 (C3b) andfactor B (Bb). Once C3 is activated to C3b, it exposes a reactivethioester that allows the peptide to covalently attach to any surface that can provide anucleophile such as a primary amine or a hydroxyl group. Activated C3 can then interact with factor B. Factor B is then activated by factor D, to form Bb. The resultant complex, C3bBb, is called the alternative pathway (AP) C3 convertase.
C3bBb is deactivated in steps. First, the proteolytic component of the convertase, Bb, is removed by complement regulatory proteins havingdecay-accelerating factor (DAF) activity. Next, C3b is broken down progressively to first iC3b, then C3c + C3dg, and then finally C3d. Factor I is the protease cleaves C3b but requires acofactor (e.gFactor H, CR1, MCP or C4BP) for activity.
Several crystallographic structures of C3 have been determined[11] and reveal that this protein contains 13 domains.[12][13][14][15] TheC3 precursor protein is first processed by the removal of 4 Arginine residues, forming two chains, beta and alpha, linked by a disulfide bond. The C3 convertase activates C3 by cleaving the alpha chain, releasing C3a anaphylatoxin and generating C3b (beta chain + alpha' (alpha prime) chain).
Factor H is the primaryregulator of C3. Deficiency of Factor H may lead to uncontrolled C3 activity through thealternative pathway of the complement system.[18]
Deficiency of C3 results in the affected person beingimmunocompromised. Specifically, they are vulnerable to bacterial pathogens, including repeat infections by the same organism, but are not susceptible to viruses. This vulnerability also occurs in an individual deficient in C1,C2,C4, or any of their required components or associated proteins, and the clinical effects are very similar regardless of the specific deficiency. This is because all of these must work with C3 for the complement system to function.[19]
Affected people are particularly vulnerable to infections with Gram-negative organisms such as pathogenicE. coli orSalmonella enterica.[20] Additionally, C3 and other complement deficiencies are associated with frequent and severerespiratory infections, as well as other infections that invade and penetrate tissue layers.[19]
Some data shows thatacquired C3 deficiency, including when this is intentionally done for medicalimmunosuppression purposes, may not significantly impact a person's immune function long-term.[21] However, by contrast,congenital C3 deficiency is known to cause chronic illness.[19]
^Wiesmann C, Katschke KJ, Yin J, Helmy KY, Steffek M, Fairbrother WJ, McCallum SA, Embuscado L, DeForge L, Hass PE, van Lookeren Campagne M (Nov 2006). "Structure of C3b in complex with CRIg gives insights into regulation of complement activation".Nature.444 (7116):217–20.Bibcode:2006Natur.444..217W.doi:10.1038/nature05263.PMID17051150.S2CID4372953.
^Fredslund F, Jenner L, Husted LB, Nyborg J, Andersen GR, Sottrup-Jensen L (Aug 2006). "The structure of bovine complement component 3 reveals the basis for thioester function".Journal of Molecular Biology.361 (1):115–27.doi:10.1016/j.jmb.2006.06.009.PMID16831446.
